FDA fast-tracks Snipr Biome's primary candidate

Snipr Biome’s CRISPR treatment of blood infections in cancer patients has been granted special status by the US Food and Drug Administration.

Photo: Snipr Biome/PR

Just two weeks after the FDA approved the development plans for Snipr Biome’s candidate, SNIPR001, the company now reveals it has been awarded fast-track status.

”At Snipr Biome, we are extremely proud to have been granted fast-track designation by the FDA. It underlines SNIPR001’s potential to be a game-changer for hematological cancer patients at increased risk of life-threatening bloodstream infections caused by E. coli,” says Christian Grøndahl, co-founder & CEO of the firm.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs